UPC_CFI_858/2025

The Lisbon Local Division (judge-rapporteur Rute Lopes) rejected Zentiva Portugal's preliminary objection challenging UPC jurisdiction over Boehringer Ingelheim's infringement action concerning EP 1 830 843 (nintedanib for treatment of idiopathic pulmonary fibrosis). The Court held that the action is an Art. 32(1)(a) UPCA infringement action based on an administrative notice (INFARMED No. 0689/2024) creating a threat of infringement, and UPC jurisdiction is properly established. Zentiva's additional argument (no demonstrated acts of manufacture etc.) was held to be a substantive merits defence outside the scope of R. 19 RoP.